FDA Recalls Finder

FDA approves Kalydeco to treat rare form of cystic fibrosis
31 January 2012, 9:59 am

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

Source: Food and Drug Administration--Press Releases